{"podcast":{"title":"Business News Today | 2 Min News | The Daily News Now!","slug":"business-finance-news-today-2-min-news-the-daily-news-now-7726192","podcast_index_feed_id":7726192,"rss_url":"https://feeds.fastcast.ai/the-daily-news-now-business.xml","website_url":"https://thednn.ai/","image_url":"https://image.fastcast.ai/cover/a77b5c94-431e-4490-8653-1f676f1da586.png","author":"The Daily News Now!","episode_count":1320,"summary":"Hosted by Corey with the Story. Stay informed with the latest business, stock market, and finance headlines, updates, and breaking stories delivered daily in quick, engaging episodes. Subscribe! The Daily News Now! — Every city. Every story. AI-powered. Advertise on DNN: advertise@thednn.ai","last_synced_at":"2026-06-17T18:18:57.837082+00:00","page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192"},"episode":{"title":"Revolution Medicines Breakthrough in Pancreatic Cancer","slug":"revolution-medicines-breakthrough-in-pancreatic-cancer","published_at":"2026-06-11T11:31:51+00:00","page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/revolution-medicines-breakthrough-in-pancreatic-cancer","show_page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192","url":"https://api.fastcast.ai/audio/6bdc203a-8ad0-42fb-995d-31df8ad25922.mp3","audio_url":"https://api.fastcast.ai/audio/6bdc203a-8ad0-42fb-995d-31df8ad25922.mp3","summary":"Revolution Medicines is rewriting the pancreatic cancer playbook with daraxonrasib, the first drug to push median survival past a year in metastatic cases—so groundbreaking it earned a standing ovation from oncologists. Now in commercial rollout mode, the company’s FDA submission is underway, while major cancer centers already treat patients via its Expanded Access Program. Targeting the RAS protein, which drives 90% of pancreatic tumors, daraxonrasib is also being tested in colorectal and lung cancers. With a pipeline of other RAS inhibitors like zoldonrasib and elironrasib, Revolution’s science hinges on a novel chaperone-binding approach. Though still unprofitable, the company’s $4 billion cash reserve gives it a two-year runway to market daraxonrasib without fundraising—and makes it a hot acquisition target. It’s a high-stakes, high-reward biotech play: massive potential upside if execution succeeds, but risk if the science or commercialization falters. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/4fc3a5981f2532b2","meta_description":"Revolution Medicines is rewriting the pancreatic cancer playbook with daraxonrasib, the first drug to push median survival past a year in metastatic cases…","key_points":[],"chapters":[],"topics":[],"duration_seconds":130,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/revolution-medicines-breakthrough-in-pancreatic-cancer/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/revolution-medicines-breakthrough-in-pancreatic-cancer.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}